Information Provided By:
Fly News Breaks for August 8, 2018
BSX
Aug 8, 2018 | 13:02 EDT
Canaccord Genuity analyst Jason Mills points out that Boston Scientific this morning announced that it will be in position to submit the final Lotus Edge premarket approval next week, with plans to be back in Europe in Q1 of 2019. The pending market re-entry of Lotus could drive "meaningful upside" to consensus expectations, especially in 2020 and beyond, Mills tells investors in a research note. He believes Lotus Edge has largely been taken out of forward estimates and keeps a Buy rating on Boston Scientific with a $39 price target.
News For BSX From the Last 2 Days
BSX
BSX
BSX
BSX
BSX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.